Document is current
Any future updates will be listed below
-
Authors
Dombernowsky, Sarah Louise https://orcid.org/0009-0006-1017-0689
Damholt, Birgitte Bentz https://orcid.org/0000-0002-0036-8345
Højby Rasmussen, Michael https://orcid.org/0000-0002-2210-0366
Sværke, Claus https://orcid.org/0009-0003-8149-841X
Kildemoes, Rasmus Juul https://orcid.org/0000-0002-0965-9333
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03905850 at ClinicalTrials.govDocuments that mention this clinical trial
Investigating the Bioavailability and Insulin-like Growth Factor-I Release of Two Different Strengths of Somapacitan: A Randomised, Double-Blind Crossover Trial
https://doi.org/10.1007/s40262-024-01395-y
-
Funding
Funding for this research was provided by:
Novo Nordisk A/S
- License Information
-
More Information
Article History
Accepted: 10 June 2024
First Online: 5 July 2024
Declarations
:
: The trial was sponsored by Novo Nordisk A/S.
: S.L.D., B.B.D., M.H.R., C.S. and R.J.K. are employees of and hold stocks in Novo Nordisk.
: The data that support the findings of this study are available on request from the corresponding author.
: The trial was conducted in accordance with the Declaration of Helsinki and ICH Good Clinical Practice guidelines. Prior to the start of the trial, the protocol, the consent form and the participant information sheet were reviewed and approved according to local regulations by appropriate health authorities and by the Ethics Committee of the North Rhine Medical Association.
: The participants were informed of the risks and benefits of the trial, and that they could withdraw from the trial at any time for any reason. Consent was obtained in writing prior to any trial-related activities.
: Not applicable.
: Not applicable.
: All authors were involved in the study conceptualisation and methodology, data review, and analysis of results and clinical trial report. S.L.D. and B.B.D. were responsible for the study conduct. All authors agreed to be accountable to all aspects of the work and to ensure any questions related to the accuracy and integrity of the work are fully investigated and resolved. All authors read and approved the final version for submission to the journal.
